5AnseU J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [J]. Chest, 2004, 126 (3 Suppl) : 204S-233S.
6Daure EW, Fuj lkawak, Kisiel W. The coagulation cascude: Initiation, maintenance and regul-ation [J]. B iochem istry, 1991, 30 (43): 10363-10370.
7The RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hiprthroplasty[J]. N Engl J Med, 2008, 358 (26): 2765-2775.
8RECORD3 Investigators. Rivaxoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty [J]. N Engl J Med, 2008, 358 (26): 2776-2786.
9The Einstein Extension Study. Once-Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recturrent Symptomatic Venous Thromboembolism In Patients With Symptomatic DeepVein Thrombosis Or Pulmonary Embolism [ EB/OL]. http : //clinicaltrials.gov/ct2/show/NCT00439725.
10Venous Thromboembolic Event (VTE) Prophylaxis in Medically III Patients (MAGELLAN) [ EB/OL]. http : //clinicaltrials. Gov/ct2/ show/NCT00571649.
